CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting: Nanomaterials and Translational Perspective
Advanced Science · 2023-07 · 10 (19)
DOI: 10.1002/advs.202207512 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Science, online erschienen am 11.05.2023. Verfasst von Deepak Kumar Sahel und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Birla Institute of Technology and Science-Pilani, BITS-Pilani, Vidya Vihar, Pilani, Rajasthan, 333031, India. Hauptthemen laut MEDLINE: Gene Editing, Nanostructures. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 264 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Clustered randomly interspaced short palindromic repeats (CRISPRs) and its associated endonuclease protein, i.e., Cas9, have been discovered as an immune system in bacteria and archaea; nevertheless, they are now being adopted as mainstream biotechnological/molecular scissors that can modulate ample genetic and nongenetic diseases via insertion/deletion, epigenome editing, messenger RNA editing, CRISPR interference, etc. Many Food and Drug Administration‐approved and ongoing clinical trials on CRISPR adopt ex vivo strategies, wherein the gene editing is performed ex vivo, followed by reimplantation to the patients. However, the in vivo delivery of the CRISPR components is still under preclinical surveillance. This review has summarized the nonviral nanodelivery strategies for gene editing using CRISPR/Cas9 and its recent advancements, strategic points of view, challenges, and future aspects for tissue‐specific in vivo delivery of CRISPR/Cas9 components using nanomaterials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Birla Institute of Technology and Science-Pilani, BITS-Pilani, Vidya Vihar, Pilani, Rajasthan, 333031, India.
- School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK.
- College of Pharmacy & Health Sciences, St. John's University, Queens, NY, 11439, USA.
- Terasaki Institute for Biomedical Innovation, Los Angeles, CA, 90064, USA.
- Department of Pharmaceutical Sciences, University of Sciences, Philadelphia, PA, 19104, USA.
- Graduate School of Pharmaceutical Sciences and School of Pharmacy, Duquesne University, Pittsburgh, PA, 15282, USA.
ORCID-Profile: Lalitkumar K Vora, Deepakkumar Mishra, Kamatham Pushpa Tryphena, Satoru Kawakita, Dharmendra Kumar Khatri, Raghu Raj Singh Thakur
Zitieren
APA
Sahel, D. K., Vora, L. K., Saraswat, A., Sharma, S., Monpara, J., D'Souza, A. A., Mishra, D., Tryphena, K. P., Kawakita, S., Khan, S., Azhar, M., Khatri, D. K., Patel, K., & Singh Thakur, R. R. (2023). CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting: Nanomaterials and Translational Perspective. Advanced Science, 10(19). https://doi.org/10.1002/advs.202207512
Vancouver
Sahel DK, Vora LK, Saraswat A, Sharma S, Monpara J, D'Souza AA, et al. CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting: Nanomaterials and Translational Perspective. Advanced Science. 2023;10(19). doi:10.1002/advs.202207512
BibTeX
@article{Sahel2023,
author = {Sahel, Deepak Kumar and Vora, Lalitkumar K and Saraswat, Aishwarya and Sharma, Saurabh and Monpara, Jasmin and D'Souza, Anisha A and Mishra, Deepakkumar and Tryphena, Kamatham Pushpa and Kawakita, Satoru and Khan, Shahid and Azhar, Mohd and Khatri, Dharmendra Kumar and Patel, Ketan and Singh Thakur, Raghu Raj},
title = {CRISPR/Cas9 Genome Editing for Tissue‐Specific In Vivo Targeting: Nanomaterials and Translational Perspective},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {19},
doi = {10.1002/advs.202207512}
}
EUVIMED